Literature DB >> 9549818

Suggestions for the presentation of quality of life data from clinical trials.

D Machin1, S Weeden.   

Abstract

Quality of life (QOL) data is complex since it is both multidimensional and longitudinal. This complexity is compounded with its unbalanced nature through missing observations as a consequence of patient non-compliance with assessment schedules, and, for example, in cancer clinical trials data absence due to patient attrition often through death. QOL data poses difficulties for presentation and analysis and hence interpretation. This paper illustrates, using data from a randomized trial of the United Kingdom Medical Research Council Lung Cancer Working Party, a step-by-step approach to presentation of QOL data. This begins with a description of compliance and its relationship with patient attrition caused by death, to a final summary profile to indicate change over time. We recognize that no single summary statistic is likely to be able to encapsulate all the subtleties of QOL data. We stress the importance of examining data graphically before performing detailed analysis and also to facilitate interpretation in the final clinical report. Although a description of analytical methods is not the purpose of this paper, we draw attention to the need for imputing missing values and to the (multi-level) modelling approach to summarizing the data, both essential adjuncts to the less formal methods described here.

Entities:  

Mesh:

Year:  1998        PMID: 9549818     DOI: 10.1002/(sici)1097-0258(19980315/15)17:5/7<711::aid-sim816>3.0.co;2-h

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

Authors:  Desmond Curran; Carmelo Pozzo; Jerzy Zaluski; Magdalena Dank; Carlo Barone; Vahur Valvere; Suayib Yalcin; Christian Peschel; Miklós Wenczl; Erdem Goker; Roland Bugat
Journal:  Qual Life Res       Date:  2009-07-01       Impact factor: 4.147

2.  Using data from studies of health-related quality of life to describe clinical issues examples from a longitudinal study of patients with advanced stages of cervical cancer.

Authors:  M Klee; M Groenvold; D Machin
Journal:  Qual Life Res       Date:  1999-12       Impact factor: 4.147

3.  The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life.

Authors:  N Tjarda Van Heek; Steve M M De Castro; Casper H van Eijck; Rutger C I van Geenen; Eric J Hesselink; Paul J Breslau; T C Khe Tran; Geert Kazemier; Mechteld R M Visser; Olivier R C Busch; Hugo Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

4.  Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma.

Authors:  M Walker; J Brown; K Brown; A Gregor; I R Whittle; R Grant
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

5.  Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review.

Authors:  Houssein Safa; Monica Tamil; Philippe E Spiess; Brandon Manley; Julio Pow-Sang; Scott M Gilbert; Firas Safa; Brian D Gonzalez; Laura B Oswald; Adele Semaan; Adi Diab; Jad Chahoud
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.